What is OncoDNA?
Founded in 2012 and headquartered in Belgium, OncoDNA operates at the intersection of biotechnology and data analytics. The company specializes in comprehensive cancer molecular profiling, providing clinicians with the actionable intelligence required to tailor therapeutic strategies to the unique genetic makeup of a patient's tumor. By integrating genomic sequencing with advanced bioinformatics, OncoDNA has established itself as a vital partner for healthcare providers seeking to move beyond one-size-fits-all treatment protocols. Its market position is defined by its commitment to clinical excellence and its ability to translate complex molecular data into clear, evidence-based clinical recommendations.
How much funding has OncoDNA raised?
OncoDNA has raised a total of $28.6M across 2 funding rounds:
Series A
$8.6M
Series B
$20M
Series A (2016): $8.6M, investors not publicly disclosed
Series B (2020): $20M led by SRIW, Swisscanto Invest, Sofinim, Sambrinvest, Inventures, Vesalius Biocapital III, The SFPI-FPIM, and CPH Bank
Key Investors in OncoDNA
SRIW
Wallonie Entreprendre acts as the economic and financial engine for the Wallonia region, providing essential capital and expertise to foster sustainable growth in deep tech and healthcare sectors.
Sambrinvest
A specialized private financial partner based in Charleroi, Sambrinvest focuses on providing tailored financing solutions to SMEs, with a strong track record in supporting life sciences and high-impact projects.
The SFPI-FPIM
The federal holding and investment company of Belgium, SFPI-FPIM manages strategic state shareholdings and invests in companies that provide significant added value to the national economy.
What's next for OncoDNA?
Looking ahead, the strategic deployment of the $20M capital is expected to focus on the international expansion of the company's diagnostic platform and the further refinement of its proprietary analytical algorithms. As the healthcare industry shifts toward personalized medicine, OncoDNA is poised to capitalize on the increasing demand for high-fidelity molecular diagnostics. The company's roadmap likely includes strengthening its collaborative network with pharmaceutical partners and research institutions to broaden the scope of its profiling services. By maintaining its focus on innovation and clinical utility, OncoDNA is set to solidify its role as a cornerstone of modern oncology, driving the next generation of therapeutic decision-making tools.
See full OncoDNA company page
